ストックスクリーナーアプリを入手
167.33
1.25%
-2.11
アフターアワーズ：
167.33
前日終値:
$169.44
開ける：
$171.78
24時間の取引高:
111.90K
Relative Volume:
0.60
時価総額：
$6.74B
収益：
-
当期純損益:
$-77.61M
株価収益率:
-72.82
EPS:
-2.2979
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.12%
1か月 パフォーマンス:
+3.49%
6か月 パフォーマンス:
+7.93%
1年 パフォーマンス:
+139.01%
1日の値動き範囲:
$167.06
$172.00
1週間の範囲:
$165.56
$178.44
52週間の値動き範囲:
$68.35
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
167.33 | 6.74B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-26 | 開始されました | BofA Securities | Buy |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-02 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Neutral |
| 2023-12-14 | 開始されました | Maxim Group | Buy |
| 2023-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 開始されました | SVB Securities | Outperform |
| 2022-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-01 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Belite Bio Inc Adr (BLTE) 最新ニュース
Belite Bio Inc ADR (NYSE: BLTE) Share Price, BLTE Stock News, BLTE Share Price & Updates - kalkine.ca
Belite Bio at H.C. Wainwright conference: tinlarebant nears FDA review By Investing.com - Investing.com Canada
Belite Bio at Morgan Stanley conference: tinlarebant nears key FDA test By Investing.com - Investing.com South Africa
Belite Bio at Cantor healthcare conference: tinlarebant advances - Investing.com India
Belite Bio at Cantor healthcare conference: tinlarebant advances By Investing.com - Investing.com Canada
Market Movers Rx: Belite Bio Leads Gainers - Pharmaceutical Executive
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs - Investing.com
Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares - investing.com
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com Nigeria
Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Belite Bio at Wells Fargo conference: nda review lifts stakes By Investing.com - Investing.com Canada
Belite Bio files Japan NDA for Stargardt disease drug - grafa.com
Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com Nigeria
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease - TipRanks
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt... - markets.businessinsider.com
Belite Bio submits drug application in Japan for Stargardt disease - Investing.com
Belite Bio (NASDAQ: BLTE) seeks Japan OK for Stargardt pill that could be a first - Stock Titan
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com South Africa
Belite Bio Pops As Wall Street Backs Stargardt Bet - TipRanks
Canaccord initiates Belite Bio stock with buy on Stargardt therapy - investing.com
Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target - finance.yahoo.com
Belite Bio Surges As Tinlarebant Nears FDA Decision - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans - Investing.com
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - Yahoo Finance
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Trading Systems Reacting to (BLTE) Volatility - Stock Traders Daily
Belite Bio to Host Virtual Commercial Day on September 2, 2026 - The Manila Times
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - The Manila Times
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Canada
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Belite Bio Inc Adr (BLTE) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):